Company intelligence / Profile preview
Xi'an Libang Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Xi'an Libang Pharmaceutical is a leading Chinese pharmaceutical company specializing in the research, development, production, and distribution of generic finished dosage forms and high-value APIs. It is recognized as the first and largest supplier of generic propofol in China with a significant market share. The company operates multiple GMP-certified manufacturing facilities for both APIs and finished formulations, with products approved by regulatory agencies including the US FDA[1][2][4]. Its pipeline consists mainly of commercialized generics across anesthesia, cardiovascular disease, pain management, imaging agents, and more.
- Therapeutic areas
- PulmonologyWomen's HealthOther
- Modalities
- Small moleculeBiologic (for some finished dosage forms and injectables)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Xi'an Libang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xi'an Libang Pharmaceutical.